Ignite Creation Date:
2024-05-05 @ 7:37 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00703859
Status:
WITHDRAWN
Last Update Posted:
2016-02-22
First Post:
2008-06-23
Brief Title:
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
Sponsor:
AHS Cancer Control Alberta
Organization:
AHS Cancer Control Alberta
Study Overview
Official Title:
A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloroacetate DCA in Patients With Newly Diagnosed Glioblastoma Multiform Tumours
Status:
WITHDRAWN
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to see whether radiotherapy plus chemotherapy Temozolomide plus Dichloroacetate DCA improves overall survival and offers better control of the disease in patients with newly diagnosed Glioblastoma Multiforme Tumours
Detailed Description:
Patients with newly diagnosed Glioblastoma Multiforme Tumours once consented to the study would undergo standard treatment of radiotherapy plus chemotherapy TMZ with DCA in pill form twice a day during the radiation phase of the study and then with TMZ for six months after Other elements of the clinical trial include pharmacokinetics and MGMT genetic testing
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None